Abivax SA (ABVX) said late Monday it closed an offering with gross proceeds of about $747.5 million, securing a 12-month cash runway following a planned submission of a new drug application for ulcerative colitis.
Each American depositary share in the 11.7 million offering represents one ordinary share.
The company expects the net proceeds, together with the cash and cash equivalents on its balance sheet, to finance its operations until Q4 2027.
The planned new drug application assumes the company will achieve positive results from its phase 3 maintenance trial of ulcerative colitis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.